Ingrid E Lundberg1, John Svensson. 1. Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Abstract
PURPOSE OF REVIEW: The idiopathic inflammatory myopathies myositis are rare diseases with limited information on risk factors for disease and prognosis. The aim of this review is to give an overview of how registries can be used in myositis research. RECENT FINDINGS: Population-based registries have been used in a number of incidence and prevalence studies in the review period and have shown myositis to be more common than previously reported. Disease-specific registries have been used for detailed studies on subphenotypes and longitudinal studies to identify prognostic markers and treatment outcomes. SUMMARY: Registries, both national healthcare and health insurance registries, as well as disease-specific clinical registries, are useful sources to investigate a rare disease like myositis. To achieve increased understanding of whether different subphenotypes differ in treatment outcome and prognosis, a large number of patients need to be followed longitudinally in a systematic way. A novel international, multidisciplinary registry, EUROMYOSITIS, has been developed. This is an open source registry with to date 20 centers and more than 2500 patients with myositis, many of whom are followed longitudinally. This registry has clear potentials for clinical and epidemiological research, as well as for clinical trial in myositis, and welcomes investigators from all over the world.
PURPOSE OF REVIEW: The idiopathic inflammatory myopathiesmyositis are rare diseases with limited information on risk factors for disease and prognosis. The aim of this review is to give an overview of how registries can be used in myositis research. RECENT FINDINGS: Population-based registries have been used in a number of incidence and prevalence studies in the review period and have shown myositis to be more common than previously reported. Disease-specific registries have been used for detailed studies on subphenotypes and longitudinal studies to identify prognostic markers and treatment outcomes. SUMMARY: Registries, both national healthcare and health insurance registries, as well as disease-specific clinical registries, are useful sources to investigate a rare disease like myositis. To achieve increased understanding of whether different subphenotypes differ in treatment outcome and prognosis, a large number of patients need to be followed longitudinally in a systematic way. A novel international, multidisciplinary registry, EUROMYOSITIS, has been developed. This is an open source registry with to date 20 centers and more than 2500 patients with myositis, many of whom are followed longitudinally. This registry has clear potentials for clinical and epidemiological research, as well as for clinical trial in myositis, and welcomes investigators from all over the world.
Authors: Lisa G Rider; Nicolino Ruperto; Angela Pistorio; Brian Erman; Nastaran Bayat; Peter A Lachenbruch; Howard Rockette; Brian M Feldman; Adam M Huber; Paul Hansen; Chester V Oddis; Ingrid E Lundberg; Anthony A Amato; Hector Chinoy; Robert G Cooper; Lorinda Chung; Katalin Danko; David Fiorentino; Ignacio García-De la Torre; Ann M Reed; Yeong Wook Song; Rolando Cimaz; Rubén J Cuttica; Clarissa A Pilkington; Alberto Martini; Janjaap van der Net; Susan Maillard; Frederick W Miller; Jiri Vencovsky; Rohit Aggarwal Journal: Rheumatology (Oxford) Date: 2017-11-01 Impact factor: 7.580
Authors: Liza J McCann; Jamie J Kirkham; Lucy R Wedderburn; Clarissa Pilkington; Adam M Huber; Angelo Ravelli; Duncan Appelbe; Paula R Williamson; Michael W Beresford Journal: Trials Date: 2015-06-12 Impact factor: 2.279
Authors: J B Lilleker; A Rietveld; S R Pye; K Mariampillai; O Benveniste; M T J Peeters; J A L Miller; M G Hanna; P M Machado; M J Parton; K R Gheorghe; U A Badrising; I E Lundberg; S Sacconi; M K Herbert; N J McHugh; B R F Lecky; C Brierley; D Hilton-Jones; J A Lamb; M E Roberts; R G Cooper; C G J Saris; G J M Pruijn; H Chinoy; B G M van Engelen Journal: Ann Rheum Dis Date: 2017-01-25 Impact factor: 19.103
Authors: Liza J McCann; Clarissa A Pilkington; Adam M Huber; Angelo Ravelli; Duncan Appelbe; Jamie J Kirkham; Paula R Williamson; Amita Aggarwal; Lisa Christopher-Stine; Tamas Constantin; Brian M Feldman; Ingrid Lundberg; Sue Maillard; Pernille Mathiesen; Ruth Murphy; Lauren M Pachman; Ann M Reed; Lisa G Rider; Annet van Royen-Kerkof; Ricardo Russo; Stefan Spinty; Lucy R Wedderburn; Michael W Beresford Journal: Ann Rheum Dis Date: 2017-10-30 Impact factor: 19.103
Authors: Juyoung Yoo; Sung Soo Ahn; Seung Min Jung; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee Journal: Korean J Intern Med Date: 2019-12-30 Impact factor: 2.884
Authors: Liza J McCann; Katie Arnold; Clarissa A Pilkington; Adam M Huber; Angelo Ravelli; Laura Beard; Michael W Beresford; Lucy R Wedderburn Journal: Pediatr Rheumatol Online J Date: 2014-07-21 Impact factor: 3.054
Authors: James B Lilleker; Jiri Vencovsky; Guochun Wang; Lucy R Wedderburn; Louise Pyndt Diederichsen; Jens Schmidt; Paula Oakley; Olivier Benveniste; Maria Giovanna Danieli; Katalin Danko; Nguyen Thi Phuong Thuy; Monica Vazquez-Del Mercado; Helena Andersson; Boel De Paepe; Jan L deBleecker; Britta Maurer; Liza J McCann; Nicolo Pipitone; Neil McHugh; Zoe E Betteridge; Paul New; Robert G Cooper; William E Ollier; Janine A Lamb; Niels Steen Krogh; Ingrid E Lundberg; Hector Chinoy Journal: Ann Rheum Dis Date: 2017-08-30 Impact factor: 19.103
Authors: Felicitas Bellutti Enders; Brigitte Bader-Meunier; Eileen Baildam; Tamas Constantin; Pavla Dolezalova; Brian M Feldman; Pekka Lahdenne; Bo Magnusson; Kiran Nistala; Seza Ozen; Clarissa Pilkington; Angelo Ravelli; Ricardo Russo; Yosef Uziel; Marco van Brussel; Janjaap van der Net; Sebastiaan Vastert; Lucy R Wedderburn; Nicolaas Wulffraat; Liza J McCann; Annet van Royen-Kerkhof Journal: Ann Rheum Dis Date: 2016-08-11 Impact factor: 19.103